Online inquiry

IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6843MR)

This product GTTS-WQ6843MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL3RA gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3563
UniProt ID P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6843MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11127MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ4776MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ12828MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ13171MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ10892MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ14061MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ2395MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ6421MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW